arrow
R

Robyn D. Gartrell

Children's Hospital of Philadelphia
H指数:24
被引数:2,687

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma
2025-11-121
PRE
PNOC025: A phase 1 study assessing the safety and tolerability of magrolimab in children and adults with recurrent or progressive malignant brain tumors

PNOC025:一项评估magrolimab在复发性或进展性恶性脑肿瘤儿童和成人患者中的安全性与耐受性的1期研究

2025-11-010
PRE
Pathomic immune biomarkers define recurrence risk in early-stage melanoma

病理免疫生物标志物定义早期黑色素瘤的复发风险

2025-10-010
OAAI
Multimodal analysis of pediatric pilocytic astrocytomas reveals tumor location-associated cellular and transcriptional heterogeneity

多模态分析揭示了儿童毛细胞型星形细胞瘤中与肿瘤位置相关的细胞和转录异质性

2025-09-010
PRE
Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma
2024-10-120
PRE
Immune Response following FLASH and Conventional Radiation in Diffuse Midline Glioma

弥漫性中线胶质瘤中闪光和常规辐射后的免疫反应

2024-07-015
OAAI
OVERALL EXPERIENCE OF TWO PHASE I CLINICAL TRIALS WITH FOCUSED ULTRASOUND-MEDIATED BLOOD BRAIN BARRIER OPENING IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH PROGRESSIVE DIPG/DMG USING A NEURONAVIGATION-BASED DEVICE
2024-06-180
OAAI
Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma

聚焦超声介导血脑屏障开放与中度大分割放射治疗脑干弥漫性中线胶质瘤安全可行

2024-03-307
OAAI
Discovery and validation of effective combination therapies targeting cell state-specific master regulator vulnerabilities by network-based protein activity inference in diffuse midline glioma
2024-03-220
PRE
A SYSTEMS BIOLOGY APPROACH TO DEFINING AND TARGETING CELL STATE-SPECIFIC MASTER REGULATOR DEPENDENCIES IN DIFFUSE MIDLINE GLIOMA
2023-06-122
OAAI
Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma

免疫疗法与高剂量放射疗法 (HDRT) 相结合可显着抑制高风险神经母细胞瘤的同系小鼠模型中的肿瘤生长

HELIYON
IF3.6
2023-06-014
OAAI